Risk factors
Iovance Biotherapeutics (IOVA) risk factors
Item 1A of every Iovance Biotherapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors78 risks10 new7 dropped19 reworded
Iovance executed a 19 percent workforce reduction in August 2025 to extend its cash runway and streamline operations.
Filed Feb 24, 2026 - FY2024 10-K risk factors75 risks
Iovance faces substantial accumulated deficits of $2.4 billion and net losses of $372.2 million in 2024 while commercializing its lead product, Amtagvi.
Filed Feb 27, 2025